This document discusses pharmacokinetics and important drug interactions for treating HIV. It describes the four components of pharmacokinetics - absorption, distribution, metabolism and excretion - and explains how the liver's cytochrome P450 system plays a key role in drug metabolism. It provides examples of cytochrome P450 inducers and inhibitors and how they can affect substrate drugs. Specifically, it notes that the antibiotic rifampin is a strong inducer that significantly decreases levels of protease inhibitors, NNRTIs, methadone and antifungals by inducing cytochrome P450. Managing interactions is important for successful HIV treatment.
Non Invasive Methods Of Estimating Pharmacokinetic ParametersThilak Chandra
This document discusses non-invasive methods for estimating pharmacokinetic parameters, specifically collection of saliva and urine as alternatives to blood sampling. It covers mechanisms of drug transport between plasma and saliva/urine, factors influencing passive diffusion, techniques for collecting saliva and urine, and methods for determining pharmacokinetic parameters like elimination rate constant from urinary excretion data. The major advantages of these non-invasive methods are that they avoid risks of blood collection and improve subject compliance.
The document discusses gastrointestinal absorption of drugs. It describes the major absorption sites in the gastrointestinal tract as the stomach, small intestine, and large intestine. It then explains the various mechanisms of drug absorption including passive diffusion, carrier-mediated transport (facilitated diffusion and active transport), ionic diffusion, ion pair transport, and endocytosis. Carrier-mediated transport uses carrier proteins or enzymes to transport drugs against or along a concentration gradient. The small intestine is noted as the primary site of drug absorption due to its large surface area and longer transit time compared to other sites.
Statistical modeling in pharmaceutical research and developmentPV. Viji
Statistical modeling in pharmaceutical research and development , Statistical Modeling , Descriptive Versus Mechanistic Modeling , Statistical Parameters Estimation , Confidence Regions , Non Linearity at the Optimum , Sensitivity Analysis , Optimal Design , Population Modeling
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
This document discusses how drug transporters affect the absorption, distribution, and excretion of drugs. It describes uptake and efflux transporters expressed in the intestine, liver, kidney, and blood-brain barrier that determine drug concentrations in tissues. Inhibition or induction of these transporters by other drugs can impact the pharmacokinetics and pharmacodynamics of victim drugs. The document then classifies and provides examples of important uptake transporters like OATPs and OCTs and efflux transporters like P-gp, BCRP, MRP2, and BSEP, noting their tissue expression and roles in drug absorption, distribution, and excretion.
Plasma Drug Concentration Time Profile
Pharmacokinetic Parameter
Pharmacodynamic Parameter
Zero, First Order & Mixed Order Kinetic
Rates & Order Of Kinetics
Pharmacokinetic Models
Application Of Pharmacokinetic
Non Invasive Methods Of Estimating Pharmacokinetic ParametersThilak Chandra
This document discusses non-invasive methods for estimating pharmacokinetic parameters, specifically collection of saliva and urine as alternatives to blood sampling. It covers mechanisms of drug transport between plasma and saliva/urine, factors influencing passive diffusion, techniques for collecting saliva and urine, and methods for determining pharmacokinetic parameters like elimination rate constant from urinary excretion data. The major advantages of these non-invasive methods are that they avoid risks of blood collection and improve subject compliance.
The document discusses gastrointestinal absorption of drugs. It describes the major absorption sites in the gastrointestinal tract as the stomach, small intestine, and large intestine. It then explains the various mechanisms of drug absorption including passive diffusion, carrier-mediated transport (facilitated diffusion and active transport), ionic diffusion, ion pair transport, and endocytosis. Carrier-mediated transport uses carrier proteins or enzymes to transport drugs against or along a concentration gradient. The small intestine is noted as the primary site of drug absorption due to its large surface area and longer transit time compared to other sites.
Statistical modeling in pharmaceutical research and developmentPV. Viji
Statistical modeling in pharmaceutical research and development , Statistical Modeling , Descriptive Versus Mechanistic Modeling , Statistical Parameters Estimation , Confidence Regions , Non Linearity at the Optimum , Sensitivity Analysis , Optimal Design , Population Modeling
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
This document discusses how drug transporters affect the absorption, distribution, and excretion of drugs. It describes uptake and efflux transporters expressed in the intestine, liver, kidney, and blood-brain barrier that determine drug concentrations in tissues. Inhibition or induction of these transporters by other drugs can impact the pharmacokinetics and pharmacodynamics of victim drugs. The document then classifies and provides examples of important uptake transporters like OATPs and OCTs and efflux transporters like P-gp, BCRP, MRP2, and BSEP, noting their tissue expression and roles in drug absorption, distribution, and excretion.
Plasma Drug Concentration Time Profile
Pharmacokinetic Parameter
Pharmacodynamic Parameter
Zero, First Order & Mixed Order Kinetic
Rates & Order Of Kinetics
Pharmacokinetic Models
Application Of Pharmacokinetic
introduction
mechanisms of protein drug binding
binding of drugs
binding of drugs to blood components
determination of protein drug binding
factors affecting
significance
This document discusses the design of dosage regimens and controlled release drug delivery systems based on pharmacokinetic principles. It begins with an introduction to pharmacokinetics and then covers factors to consider in designing dosage regimens such as dose size, dose frequency, and approaches like empirical or population-based modeling. It also discusses concepts like loading and maintenance doses, drug accumulation, and fluctuation for multiple dosing. Finally, it discusses using pharmacokinetic parameters to design controlled release formulations to optimize therapeutic effects and reduce side effects.
This document discusses various study designs used in bioequivalence studies. It describes the objectives of such studies as determining if a test product is bioequivalent to a reference product when administered at the same molar dose under similar conditions. Some key study designs discussed include non-replicated parallel studies for long-acting drugs, multiple dose steady state studies, and clinical endpoint studies comparing therapeutic effects. Special considerations are also noted for highly variable drugs.
Clinical significance of bioequivalence and biowaiversNagaraju Ravouru
1. The document discusses the clinical significance of bioequivalence studies and biowaivers. Bioequivalence studies are conducted to show that generic drug products are equivalent to innovator products in terms of rate and extent of absorption.
2. Biowaivers allow approval of drug applications without conducting in vivo bioequivalence testing based on evidence of equivalence from other factors. The Biopharmaceutics Classification System provides guidelines for biowaivers for certain drug products based on solubility and permeability characteristics.
3. There are limitations to biowaivers such as they are not applicable to locally acting or modified release drug products, or those with a narrow therapeutic index. Biowaivers can help reduce unnecessary exposure of subjects to
in vitro dissolution and iviv correlation RoshanJain35
The document summarizes a seminar presentation on in vitro dissolution and in vitro-in vivo correlation (IVIVC). It defines key terms like dissolution, IVIVC, and discusses the significance of IVIVC including its use in reducing bioequivalence studies. The document also describes the various apparatus used for in vitro dissolution testing and the parameters and levels used to establish correlations between in vitro dissolution and in vivo absorption.
The document discusses the pH partition theory of drug absorption from the gastrointestinal tract. The theory states that a drug's absorption is governed by its dissociation constant (pKa), the lipid solubility of its unionized form, and the pH of the absorption site. According to the theory, only the unionized form of an acid or base drug can be absorbed if it is sufficiently lipid soluble. The fraction of a drug in its unionized form depends on the drug's pKa and the pH of the solution based on the Henderson-Hasselbalch equation. While the pH partition theory explains many observations, it has limitations such as not accounting for the presence of an unstirred water layer and virtual membrane pH at the absorption
CLINICAL SIGNIFICANCE OF BIOEQUIVALENCE STUDIES, BIOEQUIVALENCE, REASONS TO PERFORM BIOEQUIVALENCE STUDIES , NEED FOR BIOEQUIVALENCE STUDIES, IMPORTANCE OF BIOEQUIVALANCE STUDIES, DETERMINATION OF BIOEQUIVALENCE OF A DRUG PRODUCT, CLINICAL SIGNIFICANCE.
1. Measurement of Bioavailability:
Direct and indirect methods may be used to assess drug bioavailability. The in-vivo bioavailability of a drug product is demonstrated by the rate and extent of drug absorption, as determined by comparison of measured parameters, e.g., concentration of the active drug ingredient in the blood, cumulative urinary excretion rates, or pharmacological effects.
For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
The design of the bioavailability study depends on the objectives of the study, the ability to analyze the drug (and metabolites) in biological fluids, the pharmacodynamics of the drug substance, the route of drug administration, and the nature of the drug product.
Pharmacokinetic and/or pharmacodynamic parameters as well as clinical observations and in-vitro studies may be used to determine drug bioavailability from a drug product.
1.1. Pharmacokinetic methods:
These are very widely used and based upon the assumption that the pharmacokinetic profile reflects the therapeutic effectiveness of a drug. Thus these are indirect methods. The two major pharmacokinetic methods are:
The major pharmacokinetic methods are:
Plasma / blood level time profile.
o Time for peak plasma (blood) concentration (t max)
o Peak plasma drug concentration (Cmax)
o Area under the plasma drug concentration–time curve (AUC)
Urinary excretion studies.
o Cumulative amount of drug excreted in the urine (Du)
o Rate of drug excretion in the urine (dDu/dt)
o Time for maximum urinary excretion (t)
C. Other biological fluids
1.2. Pharmacodynamic methods:
IT involves direct measurement of drug effect on a (patho) physiological process as a function of time. Disadvantages of it may be high variability, difficult to measure, limited choices, less reliable, more subjective, drug response influenced by several physiological & environmental factors.
They involve determination of bioavailability from:
Acute pharmacological response.
Therapeutic response.
1.3. In-vitro dissolution studies
Closed compartment apparatus
Open compartment apparatus
Dialysis systems.
1.4. Clinical observations
Well-controlled clinical trials
This document discusses in-vivo methods for determining drug permeability and absorption. It describes two main types of in-vivo methods: direct and indirect. The direct method involves measuring drug levels in blood or urine over time after administration to determine the rate and extent of absorption. The indirect method measures pharmacological response instead of drug concentration when direct measurement is difficult. In-vivo methods provide a more precise understanding of factors like gastric emptying and drug effects on the gastrointestinal tract compared to in-vitro or in situ methods.
DISSOLUTION
Dissolution is a process in which solid substance solubilizes in a given solvent
DISSOLUTION TESTING
A dissolution test uses an apparatus with specific test conditions in combination with acceptance criteria to evaluate the performance of the product. In-vitro test must predict the in-vivo behaviour
Factors in design of dissolution tests:
Factors relating to dissolution apparatus
Factors relation to dissolution fluid
Process parameters
Need of Dissolution Testing:
Development and optimisation of dosage forms
Batch to batch drug release uniformity
Quality, safety, efficacy and stability of the product
IVIV Correlation
Bioequivalence
Assessing pre and post approval changes
DISSOLUTION APPARATUS
Dissolution apparatus evolved to prepare a sample under controlled conditions thereby making the test repeatable.
Principle types of dissolution apparatus-
Close-compartment apparatus
Open-compartment apparatus
Dialysis systems
Ideal features of Dissolution Apparatus:
The fabrication, dimensions, and positioning of all components must be precisely specified and reproducible
Simple in design, easy to operate and useable
Sensitive
Nearly perfect sink conditions
Provide an easy means of introducing the dosage form into the dissolution medium
Provide minimum mechanical abrasion
Easy withdrawal of samples
Elimination of evaporation of solvent medium
DISSOLUTION METHODS
The Standard Dissolution Methods Database has been prepared by the Division of Bioequivalence, Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA).
Official methods:
Rotating Basket
Rotating Paddle
Reciprocating Cylinder
Flow-Through Cell
Paddle Over Disc
Rotating Cylinder
Reciprocating Disc
Non-official methods:
Static Disc Method
Beaker Method
Flask Stirrer Method
Peristalsis Method
Rotating Bottle Method
Dialysis Method
Diffusion Cell Method
Dissolution Apparatus Types and their Applications
Problems associated with dissolution apparatus
USP Performance Verification Test (PVT):
The USP Performance Verification Test (PVT) assesses the suitable performance of apparatus used in dissolution testing.
Responsible for detecting problems associated with the dissolution apparatus that are found to be within mechanical tolerances.
REFERENCES
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptxPawanDhamala1
The document discusses descriptive versus mechanistic modeling approaches. Descriptive models describe overall system behavior without claiming to represent underlying mechanisms, while mechanistic models directly correspond to real system components and interactions. Key differences are that descriptive models are empirical and incremental, while mechanistic models have tangible system representations but can be challenging due to nonlinearity and noise. The objectives of modeling are reducing drug discovery costs and times through experiment iteration and model improvement.
The release of the drug substance from the drug product leading to the bioavailability of the drug substance. The assessment of drug product performance is imp. Since bioavailability is related both to the pharmacodynamic responses and the adverse events. The performance tests relate the quality of a drug product to clinical safety and efficacy.
Bioavailability studies are drug product performance studies used to define
the effect of changes in the physicochemical properties of the drug substance, the formulation of the drug, and the manufacturing process of the drug product.
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNN Anusha
BIOPHARMACEUTICS studies the in vitro impact of physicochemical properties of drugs and drug products on delivery to body under normal or pathologic conditions.
Biopharmaceutics links the physical and chemical properties of drug and drug product to their performance, in vivo.
The aim of biopharmaceutics is to adjust the delivery of drug from drug products in such a manner as to provide: optimal therapeutic activity and safety for the patient.
This document discusses bioavailability and bioequivalence studies, which are essential to ensure uniform quality, efficacy, and safety of pharmaceutical products. Bioavailability refers to the amount and rate of drug absorption from its dosage form into systemic circulation. Bioequivalence compares the rate and extent of absorption of a test product to a reference product. The document outlines various study designs used in bioequivalence studies, including crossover, parallel, and replicated designs. It also discusses the statistical evaluation of these studies and requirements for establishing bioequivalence.
This document compares different methods for comparing dissolution profiles of drug products. It defines dissolution profile comparison and its objectives such as developing bioequivalent products and in vitro-in vivo correlations. Graphical, statistical, model-dependent and model-independent methods are described. The most common model-independent method is the f2 similarity factor test recommended by the FDA, which provides a single value to determine if two dissolution profiles are similar based on the percent dissolved over time. Proper selection of time points and criteria for coefficient of variation are important for f2 testing.
Computational modeling in drug dispositionHimal Barakoti
The document discusses computational modeling of drug disposition. It covers modeling of drug absorption, distribution, excretion, and active transport. For drug absorption, it describes modeling of solubility, intestinal permeability, and transporters involved. It also discusses modeling approaches for distribution processes like volume of distribution, plasma protein binding, and blood-brain barrier permeability. Current challenges include better incorporating the effects of active transporters in models. The document emphasizes that while computational models are useful for predicting drug properties, fully accounting for complex biological factors remains difficult.
Drug product performance , in vivo: bioavailability and bioequivalenceDipakKumarGupta3
1. Bioavailability studies assess how much of a drug reaches systemic circulation after administration. They are used to define the effects of changes to a drug's formulation or manufacturing process.
2. Key parameters measured include Cmax, Tmax, and AUC, which provide information about a drug's absorption rate and extent. Bioequivalence studies compare these parameters between generic and brand name drugs to ensure equivalent therapeutic effects.
3. Common study designs include single-dose fasting studies, food effect studies, and multiple-dose steady state studies. These follow standard crossover or parallel designs to compare test and reference drug products administered to healthy subjects.
Cellular uptake of drugs can occur through passive diffusion of small molecules or active transport of larger particles via endocytosis, exocytosis, phagocytosis, or pinocytosis. Transport across epithelial barriers relies on passive diffusion, carriers, or endocytosis. Extravasation from blood vessels depends on permeability and physicochemical drug properties, while lymphatic uptake drains drug molecules from tissues. The reticuloendothelial system phagocytoses pathogens and debris from circulation and tissues.
There are significant drug interactions between antiretroviral drugs and other medications that must be carefully managed. An introductory case involves a woman taking phenytoin and cotrimoxazole who is starting antiretroviral therapy including nevirapine, lamivudine and zidovudine. Nevirapine may decrease phenytoin levels, so phenytoin dosing may need adjustment to avoid loss of seizure control. Cotrimoxazole interacts with phenytoin as well, but discontinuing it is not necessary as the patient has been stable on both medications. The document discusses mechanisms of antiretroviral drug interactions and provides examples of interactions between classes of
This document discusses several potential drug-drug interactions involving various medications:
1. A woman taking simvastatin, diltiazem, aspirin is prescribed clarithromycin. Clarithromycin is a strong CYP3A4 inhibitor and may significantly increase simvastatin levels, increasing risk of side effects like rhabdomyolysis. The patient's simvastatin dose should not exceed 40 mg daily while taking clarithromycin.
2. Minocycline is unlikely to reduce the effectiveness of a low-dose combined oral contraceptive. Any interaction would be due to suppressed gut bacteria and is considered very rare.
3. A man's phenytoin levels increased after starting flu
introduction
mechanisms of protein drug binding
binding of drugs
binding of drugs to blood components
determination of protein drug binding
factors affecting
significance
This document discusses the design of dosage regimens and controlled release drug delivery systems based on pharmacokinetic principles. It begins with an introduction to pharmacokinetics and then covers factors to consider in designing dosage regimens such as dose size, dose frequency, and approaches like empirical or population-based modeling. It also discusses concepts like loading and maintenance doses, drug accumulation, and fluctuation for multiple dosing. Finally, it discusses using pharmacokinetic parameters to design controlled release formulations to optimize therapeutic effects and reduce side effects.
This document discusses various study designs used in bioequivalence studies. It describes the objectives of such studies as determining if a test product is bioequivalent to a reference product when administered at the same molar dose under similar conditions. Some key study designs discussed include non-replicated parallel studies for long-acting drugs, multiple dose steady state studies, and clinical endpoint studies comparing therapeutic effects. Special considerations are also noted for highly variable drugs.
Clinical significance of bioequivalence and biowaiversNagaraju Ravouru
1. The document discusses the clinical significance of bioequivalence studies and biowaivers. Bioequivalence studies are conducted to show that generic drug products are equivalent to innovator products in terms of rate and extent of absorption.
2. Biowaivers allow approval of drug applications without conducting in vivo bioequivalence testing based on evidence of equivalence from other factors. The Biopharmaceutics Classification System provides guidelines for biowaivers for certain drug products based on solubility and permeability characteristics.
3. There are limitations to biowaivers such as they are not applicable to locally acting or modified release drug products, or those with a narrow therapeutic index. Biowaivers can help reduce unnecessary exposure of subjects to
in vitro dissolution and iviv correlation RoshanJain35
The document summarizes a seminar presentation on in vitro dissolution and in vitro-in vivo correlation (IVIVC). It defines key terms like dissolution, IVIVC, and discusses the significance of IVIVC including its use in reducing bioequivalence studies. The document also describes the various apparatus used for in vitro dissolution testing and the parameters and levels used to establish correlations between in vitro dissolution and in vivo absorption.
The document discusses the pH partition theory of drug absorption from the gastrointestinal tract. The theory states that a drug's absorption is governed by its dissociation constant (pKa), the lipid solubility of its unionized form, and the pH of the absorption site. According to the theory, only the unionized form of an acid or base drug can be absorbed if it is sufficiently lipid soluble. The fraction of a drug in its unionized form depends on the drug's pKa and the pH of the solution based on the Henderson-Hasselbalch equation. While the pH partition theory explains many observations, it has limitations such as not accounting for the presence of an unstirred water layer and virtual membrane pH at the absorption
CLINICAL SIGNIFICANCE OF BIOEQUIVALENCE STUDIES, BIOEQUIVALENCE, REASONS TO PERFORM BIOEQUIVALENCE STUDIES , NEED FOR BIOEQUIVALENCE STUDIES, IMPORTANCE OF BIOEQUIVALANCE STUDIES, DETERMINATION OF BIOEQUIVALENCE OF A DRUG PRODUCT, CLINICAL SIGNIFICANCE.
1. Measurement of Bioavailability:
Direct and indirect methods may be used to assess drug bioavailability. The in-vivo bioavailability of a drug product is demonstrated by the rate and extent of drug absorption, as determined by comparison of measured parameters, e.g., concentration of the active drug ingredient in the blood, cumulative urinary excretion rates, or pharmacological effects.
For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
The design of the bioavailability study depends on the objectives of the study, the ability to analyze the drug (and metabolites) in biological fluids, the pharmacodynamics of the drug substance, the route of drug administration, and the nature of the drug product.
Pharmacokinetic and/or pharmacodynamic parameters as well as clinical observations and in-vitro studies may be used to determine drug bioavailability from a drug product.
1.1. Pharmacokinetic methods:
These are very widely used and based upon the assumption that the pharmacokinetic profile reflects the therapeutic effectiveness of a drug. Thus these are indirect methods. The two major pharmacokinetic methods are:
The major pharmacokinetic methods are:
Plasma / blood level time profile.
o Time for peak plasma (blood) concentration (t max)
o Peak plasma drug concentration (Cmax)
o Area under the plasma drug concentration–time curve (AUC)
Urinary excretion studies.
o Cumulative amount of drug excreted in the urine (Du)
o Rate of drug excretion in the urine (dDu/dt)
o Time for maximum urinary excretion (t)
C. Other biological fluids
1.2. Pharmacodynamic methods:
IT involves direct measurement of drug effect on a (patho) physiological process as a function of time. Disadvantages of it may be high variability, difficult to measure, limited choices, less reliable, more subjective, drug response influenced by several physiological & environmental factors.
They involve determination of bioavailability from:
Acute pharmacological response.
Therapeutic response.
1.3. In-vitro dissolution studies
Closed compartment apparatus
Open compartment apparatus
Dialysis systems.
1.4. Clinical observations
Well-controlled clinical trials
This document discusses in-vivo methods for determining drug permeability and absorption. It describes two main types of in-vivo methods: direct and indirect. The direct method involves measuring drug levels in blood or urine over time after administration to determine the rate and extent of absorption. The indirect method measures pharmacological response instead of drug concentration when direct measurement is difficult. In-vivo methods provide a more precise understanding of factors like gastric emptying and drug effects on the gastrointestinal tract compared to in-vitro or in situ methods.
DISSOLUTION
Dissolution is a process in which solid substance solubilizes in a given solvent
DISSOLUTION TESTING
A dissolution test uses an apparatus with specific test conditions in combination with acceptance criteria to evaluate the performance of the product. In-vitro test must predict the in-vivo behaviour
Factors in design of dissolution tests:
Factors relating to dissolution apparatus
Factors relation to dissolution fluid
Process parameters
Need of Dissolution Testing:
Development and optimisation of dosage forms
Batch to batch drug release uniformity
Quality, safety, efficacy and stability of the product
IVIV Correlation
Bioequivalence
Assessing pre and post approval changes
DISSOLUTION APPARATUS
Dissolution apparatus evolved to prepare a sample under controlled conditions thereby making the test repeatable.
Principle types of dissolution apparatus-
Close-compartment apparatus
Open-compartment apparatus
Dialysis systems
Ideal features of Dissolution Apparatus:
The fabrication, dimensions, and positioning of all components must be precisely specified and reproducible
Simple in design, easy to operate and useable
Sensitive
Nearly perfect sink conditions
Provide an easy means of introducing the dosage form into the dissolution medium
Provide minimum mechanical abrasion
Easy withdrawal of samples
Elimination of evaporation of solvent medium
DISSOLUTION METHODS
The Standard Dissolution Methods Database has been prepared by the Division of Bioequivalence, Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA).
Official methods:
Rotating Basket
Rotating Paddle
Reciprocating Cylinder
Flow-Through Cell
Paddle Over Disc
Rotating Cylinder
Reciprocating Disc
Non-official methods:
Static Disc Method
Beaker Method
Flask Stirrer Method
Peristalsis Method
Rotating Bottle Method
Dialysis Method
Diffusion Cell Method
Dissolution Apparatus Types and their Applications
Problems associated with dissolution apparatus
USP Performance Verification Test (PVT):
The USP Performance Verification Test (PVT) assesses the suitable performance of apparatus used in dissolution testing.
Responsible for detecting problems associated with the dissolution apparatus that are found to be within mechanical tolerances.
REFERENCES
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptxPawanDhamala1
The document discusses descriptive versus mechanistic modeling approaches. Descriptive models describe overall system behavior without claiming to represent underlying mechanisms, while mechanistic models directly correspond to real system components and interactions. Key differences are that descriptive models are empirical and incremental, while mechanistic models have tangible system representations but can be challenging due to nonlinearity and noise. The objectives of modeling are reducing drug discovery costs and times through experiment iteration and model improvement.
The release of the drug substance from the drug product leading to the bioavailability of the drug substance. The assessment of drug product performance is imp. Since bioavailability is related both to the pharmacodynamic responses and the adverse events. The performance tests relate the quality of a drug product to clinical safety and efficacy.
Bioavailability studies are drug product performance studies used to define
the effect of changes in the physicochemical properties of the drug substance, the formulation of the drug, and the manufacturing process of the drug product.
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNN Anusha
BIOPHARMACEUTICS studies the in vitro impact of physicochemical properties of drugs and drug products on delivery to body under normal or pathologic conditions.
Biopharmaceutics links the physical and chemical properties of drug and drug product to their performance, in vivo.
The aim of biopharmaceutics is to adjust the delivery of drug from drug products in such a manner as to provide: optimal therapeutic activity and safety for the patient.
This document discusses bioavailability and bioequivalence studies, which are essential to ensure uniform quality, efficacy, and safety of pharmaceutical products. Bioavailability refers to the amount and rate of drug absorption from its dosage form into systemic circulation. Bioequivalence compares the rate and extent of absorption of a test product to a reference product. The document outlines various study designs used in bioequivalence studies, including crossover, parallel, and replicated designs. It also discusses the statistical evaluation of these studies and requirements for establishing bioequivalence.
This document compares different methods for comparing dissolution profiles of drug products. It defines dissolution profile comparison and its objectives such as developing bioequivalent products and in vitro-in vivo correlations. Graphical, statistical, model-dependent and model-independent methods are described. The most common model-independent method is the f2 similarity factor test recommended by the FDA, which provides a single value to determine if two dissolution profiles are similar based on the percent dissolved over time. Proper selection of time points and criteria for coefficient of variation are important for f2 testing.
Computational modeling in drug dispositionHimal Barakoti
The document discusses computational modeling of drug disposition. It covers modeling of drug absorption, distribution, excretion, and active transport. For drug absorption, it describes modeling of solubility, intestinal permeability, and transporters involved. It also discusses modeling approaches for distribution processes like volume of distribution, plasma protein binding, and blood-brain barrier permeability. Current challenges include better incorporating the effects of active transporters in models. The document emphasizes that while computational models are useful for predicting drug properties, fully accounting for complex biological factors remains difficult.
Drug product performance , in vivo: bioavailability and bioequivalenceDipakKumarGupta3
1. Bioavailability studies assess how much of a drug reaches systemic circulation after administration. They are used to define the effects of changes to a drug's formulation or manufacturing process.
2. Key parameters measured include Cmax, Tmax, and AUC, which provide information about a drug's absorption rate and extent. Bioequivalence studies compare these parameters between generic and brand name drugs to ensure equivalent therapeutic effects.
3. Common study designs include single-dose fasting studies, food effect studies, and multiple-dose steady state studies. These follow standard crossover or parallel designs to compare test and reference drug products administered to healthy subjects.
Cellular uptake of drugs can occur through passive diffusion of small molecules or active transport of larger particles via endocytosis, exocytosis, phagocytosis, or pinocytosis. Transport across epithelial barriers relies on passive diffusion, carriers, or endocytosis. Extravasation from blood vessels depends on permeability and physicochemical drug properties, while lymphatic uptake drains drug molecules from tissues. The reticuloendothelial system phagocytoses pathogens and debris from circulation and tissues.
There are significant drug interactions between antiretroviral drugs and other medications that must be carefully managed. An introductory case involves a woman taking phenytoin and cotrimoxazole who is starting antiretroviral therapy including nevirapine, lamivudine and zidovudine. Nevirapine may decrease phenytoin levels, so phenytoin dosing may need adjustment to avoid loss of seizure control. Cotrimoxazole interacts with phenytoin as well, but discontinuing it is not necessary as the patient has been stable on both medications. The document discusses mechanisms of antiretroviral drug interactions and provides examples of interactions between classes of
This document discusses several potential drug-drug interactions involving various medications:
1. A woman taking simvastatin, diltiazem, aspirin is prescribed clarithromycin. Clarithromycin is a strong CYP3A4 inhibitor and may significantly increase simvastatin levels, increasing risk of side effects like rhabdomyolysis. The patient's simvastatin dose should not exceed 40 mg daily while taking clarithromycin.
2. Minocycline is unlikely to reduce the effectiveness of a low-dose combined oral contraceptive. Any interaction would be due to suppressed gut bacteria and is considered very rare.
3. A man's phenytoin levels increased after starting flu
Most current highly active antiretroviral therapy (HAART) regimens for HIV-positive patients contain two nucleoside reverse transcriptase inhibitors (NRTIs) with either a Protease inhibitor (PIs) or a non-nucleoside reverse transcriptase inhibitors (NNRTI). Notwithstanding the regulatory guidelines recommending therapeutic drug monitoring (TDM) for these drugs, therapeutic failure is a very serious concern implying drug induced toxicity and more importantly viral rebound and viral resistance.
Single dose, steady state and dose ranging studies have all more or less demonstrated that there is a positive correlation between plasma concentrations and therapeutic effects of anti-retrovirals (ARVs). However, one of the main challenges still seems to be the target concentrations for these drugs and their relevant inhibitory quotient. In this talk, we are going to examine these issues along with bioanalytical challenges, drug-effect and drug –toxicity relationships and finally drug-drug interactions within different HAART regimes.
Antibiotics requiring therapeutic drug monitoring(1)Mahen Kothalawala
This document provides information on therapeutic drug monitoring of aminoglycosides and vancomycin. It discusses pharmacokinetics concepts such as absorption, distribution, metabolism, and elimination of drugs. It explains that intravenous administration provides full bioavailability without first-pass metabolism. The document also covers pharmacodynamics predictors of antibiotic efficacy like time above MIC, AUC/MIC ratio, and Cmax/MIC ratio. It states that aminoglycosides and vancomycin require therapeutic drug monitoring due to their narrow therapeutic indices to ensure efficacy and prevent toxicity.
This document discusses various aspects of phase I drug metabolism. It begins by defining phase I metabolism as the modification of drugs through oxidation, reduction, and hydrolysis. Some of the key enzymes involved in phase I reactions include cytochrome P450 enzymes, cholinesterases, monoamine oxidases, and alcohol dehydrogenases. Specific substrates and inhibitors of various cytochrome P450 isoenzymes are listed. General inducers and inhibitors of CYP3A4 are identified. Phase I metabolism of biogenic amines by monoamine oxidase and the oxidation pathway of different alcohols are briefly described. A clinical vignette is provided regarding a patient presenting with intoxication from ingestion of an alcohol.
This document discusses drug interactions, including:
- Definitions of drug interactions and the agents involved
- Epidemiology showing drug-drug interactions cause hospitalizations and emergency visits
- Mechanisms of interactions, including pharmacokinetic processes like absorption, distribution, metabolism and excretion, and pharmacodynamic processes
- Specific examples of drug interactions involving enzyme induction or inhibition affecting metabolism
- Interactions can have outcomes like increased effects, decreased effects, or new adverse effects
This document discusses anti-HIV drugs, their mechanisms of action, and treatment regimens. It describes established drug targets for anti-HIV drugs like CCR5 coreceptors and reverse transcriptase. It provides details on first line treatment regimens including two NRTIs with an NNRTI or PI/r. It also discusses treatment failure, adverse effects, special populations, and co-infections.
03.03 management of patients on antiretroviral drugs changiDavid Ngogoyo
This document discusses rational approaches to changing or stopping antiretroviral (ART) drug regimens. It describes three main reasons for altering a patient's regimen: drug toxicity/intolerance, drug interactions, and treatment failure. It provides examples of specific adverse drug reactions and interactions to watch for with different drug classes and combinations. It emphasizes managing side effects, avoiding interactions, confirming treatment failure before changing regimens, and involving experts in complicated cases.
03.03 management of patients on antiretroviral drugs changiDavid Ngogoyo
This document provides guidance on changing or stopping antiretroviral therapy (ART) in a rational manner. It describes the main reasons for altering a patient's ART regimen as drug toxicity, interactions, or treatment failure. It discusses how to diagnose and manage common adverse drug reactions and interactions. It emphasizes the importance of assessing adherence before changing a patient's failing regimen and consulting national treatment guidelines and experts when making decisions about second-line therapy.
Therapeutic objective (prevention of DVT) Choose drug & dosing regimen (warfarin od) Monitor therapeutic and toxic response (INR and bleeding) PK PD Initiation and management of drug therapy
Drug levels can be monitored to ensure they remain within a therapeutic range. This involves repeated dosing to maintain steady state levels between a lower limit for adequate effect and an upper limit to avoid toxicity for drugs with a narrow therapeutic index or variable pharmacokinetics. Factors like liver or kidney function and drug interactions can impact drug clearance and require dosing adjustments.
The document discusses therapeutic drug monitoring (TDM), including choosing a drug and dosing regimen for a therapeutic objective, monitoring the therapeutic and toxic response, and managing drug therapy. It provides examples of TDM for various drugs, noting their therapeutic ranges, toxicity risks, and factors that influence pharmacokinetics and clearance. Close monitoring of drug levels is especially important for drugs with a low therapeutic index or highly variable pharmacokinetics.
Drug use in hepatic and renal impairmentAkshil Mehta
- Drugs are more likely to accumulate and cause toxicity in patients with impaired liver or kidney function due to reduced drug metabolism and excretion. The pharmacokinetics of many drugs are altered in patients with hepatic or renal impairment.
- In liver disease, drug absorption, metabolism, protein binding, and elimination can all be affected. Dosage reductions are often required for drugs that are metabolized by the liver. Hepatotoxic drugs should be avoided when possible.
- In kidney disease, drug absorption and excretion may be altered. Drugs that are weak acids or bases can be "trapped" in the urine through changes in urine pH. Dosage adjustments are often needed for drugs excreted by
Pharmacokinetics Drug drug interaction [Best one]abdelrahman_asar
This document summarizes various aspects of pharmacokinetic drug interactions. It discusses how the absorption, distribution, metabolism, and excretion of one drug can be altered by another drug, leading to changes in effects. Specific examples are provided of drugs that interact by inhibiting or inducing metabolic enzymes, competing for transporters, or displacing protein binding, which can increase or decrease drug levels and potentially cause adverse effects. Close monitoring is recommended when drugs with a risk of these pharmacokinetic interactions are prescribed together.
This document discusses principles of applied pharmacokinetics in critically ill adult patients. It covers topics like why pharmacokinetics is important, the four components of pharmacokinetics (absorption, distribution, metabolism, excretion), factors affecting drug absorption like routes of administration and the gastrointestinal tract, distribution and protein binding, phases of drug metabolism, and considerations for drug dosing in renal impairment. Case examples are provided to demonstrate practical applications of pharmacokinetic principles.
This document discusses drug interactions, providing examples of potential interactions between antiretroviral drugs and other medications. It defines a drug interaction as when one drug affects another, and describes types of interactions including pharmacokinetic and pharmacodynamic. The document examines case studies of patients taking multiple drugs and identifies possible interaction issues, such as between ketoconazole and an antiretroviral regimen. It emphasizes the importance of considering interactions when starting or changing medications.
TDM is increasingly being used in clinical practice in order to improve the therapeutic outcome and reducing the toxicity in HIV infection.
The use of TDM requires certain criteria in order to interpret the plasma concentrations appropriately.
1. Current therapy for tuberculosis (TB) follows several basic principles including using more than one drug, taking drugs at the appropriate dose and regularly, and continuing drugs for a sufficient period of time.
2. Directly observed therapy (DOT) is the best way to ensure patients complete appropriate TB treatment. Studies show DOT is associated with lower rates of drug resistance and relapse compared to standard self-administered therapy.
3. Treatment of drug-resistant TB requires using at least four effective drugs, including a parenteral agent. Management requires careful review of previous medications and regimens to determine effective treatment.
This document discusses the significance of pharmacokinetics in drug development and safety. It covers the typical life history of a drug in the body, from absorption to excretion. Drug development takes 10-15 years and costs $800 million-$1 billion on average, with only a 10% chance of success, often due to poor pharmacokinetic properties. Factors like toxicity, lack of efficacy, and pharmacokinetics account for the majority of failures in clinical trials. Careful consideration of a drug's pharmacokinetics is needed to ensure safety, efficacy, and appropriate dosing for patients.
Lab Results Interpretation for Pharmacist A.NouriAhmed Nouri
PHARMACISTS dealing with LAB RESULTS reading, each pharmacist needs to have the basic knowledge regarding lab results and how to deal with it . Ahmed Nouri, PharmD
Jews began settling in the American colonies in the 1600s, establishing communities in cities like Newport, Savannah, and Charleston. By the Revolutionary War, there were around 2,000 Jews living in America who played an important role in financing the patriot cause. In the 19th century, waves of Jewish immigration from Germany and Eastern Europe dramatically increased the Jewish population in America. Jewish Americans made significant contributions across all areas of American life despite facing discrimination at times.
Hedge funds are direct partnerships between fund managers and investors where managers typically invest significant personal capital, aligning interests. The modern hedge fund industry traces back to 1949 when Alfred Winslow Jones employed a strategy of offsetting long and short positions to better manage risk. Hedge funds invest in a range of assets like stocks, bonds, commodities and futures to maximize returns while minimizing risk through diversification and hedging. They provide benefits to local communities and institutions by helping fund pensions, universities, non-profits and providing stable returns over time.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the physiology of hemostasis, including:
- The essential components of hemostasis including platelet plug formation, coagulation pathways, and fibrinolysis.
- Conditions that can increase the risk of uncontrolled bleeding during surgery such as patient comorbidities, anticoagulant medications, hypothermia and acidosis.
- How achieving optimal hemostasis requires balancing procoagulant, anticoagulant, fibrinolytic and antifibrinolytic factors.
The document discusses the benefits of meditation for reducing stress and anxiety. Regular meditation practice can help calm the mind and body by lowering heart rate and blood pressure. Studies have shown that meditating for just 10-20 minutes per day can have significant positive impacts on both mental and physical health over time.
The document discusses antidotes for poisoning treatment. It defines an antidote as a therapeutic substance used to counteract the toxic effects of a xenobiotic. Antidotes are classified according to their mode or site of action, and include physical, chemical, and pharmacological antidotes. Physical antidotes like activated charcoal work by adsorption. Chemical antidotes form non-toxic complexes with toxins or accelerate detoxification. Pharmacological antidotes counteract toxins by antagonism at receptor sites, blocking toxic effects, or aiding normal function restoration. The proper use of antidotes combined with supportive care can significantly reduce morbidity and mortality from poisonings.
1) Venus gets angry that Psyche's beauty is receiving worship instead of her own and tasks Cupid with making Psyche fall in love with a monster. However, Cupid himself falls for Psyche.
2) Cupid tricks Psyche's family into leaving her on a mountain where he visits her at night. They fall deeply in love though Psyche cannot see Cupid.
3) Psyche's curious sisters convince her to look at Cupid in the dark, causing him to flee after she wakes him. Psyche must complete difficult tasks from Venus to be reunited with Cupid.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The Tempest is Shakespeare's play about Prospero, the exiled Duke of Milan, who uses magic to summon a storm that shipwrecks his enemies on the island where he and his daughter Miranda live. Prospero plots to take his revenge through illusions and tricks created by his spirit servant Ariel. The tempest brings together the royal families of Naples and Milan, and Miranda falls in love with Ferdinand, the son of the King of Naples. In the end, Prospero forgives his enemies and agrees to return to Milan while giving up his magic.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise stimulates the production of endorphins in the brain which elevate mood and reduce stress levels.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise boosts blood flow, releases endorphins, and promotes changes in the brain which help enhance one's emotional well-being and mental clarity.
This document discusses long-term side effects of the oral hypoglycemic drug sulfonylureas, which are used to treat type 2 diabetes. Sulfonylureas work by stimulating insulin release from the pancreas. However, they can sometimes cause hypoglycemia by producing too much insulin. Symptoms of hypoglycemia include headaches, confusion, and seizures. Studies have also linked long-term sulfonylurea use to increased risk of heart disease in women with diabetes. While lifestyle changes and natural remedies are gaining popularity for managing diabetes, they may also interact with drugs and cause hypoglycemia. More research is still needed on natural alternatives for treating drug-induced side effects.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
2. 2
Learning Objectives
By the end of this session, participants will be
able to:
Describe 4 components of pharmacokinetics
Explain importance of the liver’s P450
system in drug metabolism
Explain how an inducer and an inhibitor
affect the blood level of CYP450 substrates
Describe the most important drug-drug
interactions
3. 3
What is Pharmacokinetics?
The study of how drugs enter,
interact with, and leave the body,
including:
• Absorption
• Distribution
• Metabolism
• Excretion
Or, “what the body does to the drug”
4. 4
Drug Absorption
The movement of a drug from its site
of administration (stomach, vein,
skin, etc.) into the bloodstream
5. 5
Factors Affecting Drug
Absorption
Alterations in gastric pH:
• some drugs are absorbed better in an
acidic environment (itraconazole)
• other drugs are absorbed better in a
higher pH environment (ddI)
Presence or absence of food or other
medications:
• Buffered ddI decreases the absorption of
itraconazole, ketoconazole, indinivir
6. 6
Drug Distribution
Following absorption or systemic
administration into the bloodstream,
a drug distributes into interstitial and
intracellular fluids and then finally
into the body tissue
7. 7
Factors Affecting Drug
Distribution
Cardiac output and blood flow to
organs and tissues
Drug permeability and accumulation
in tissues
Protein binding:
• Protein binding varies among ARVs
• Protein levels may vary between and
within patients
8. 8
What is Drug Metabolism?
The process of transforming active
drugs into inactive metabolites that
can be more readily excreted from
the body
9. 9
Drug Excretion
Drugs are eliminated from the body
either unchanged or as metabolites:
• Kidney
• Liver-Intestines
Factors affecting drug excretion
include:
• Renal insufficiency and/or failure
• Alkalinization or acidification of urine
• Liver failure
12. 12
Cytochrome P450 Enzymes
The cytochrome P450 (CYP) enzyme
family is the major enzyme system
involved in drug metabolism
CYP-mediated metabolism occurs
mostly in the liver
CYP3A is the most important enzyme
• responsible for the breakdown and
clearance of the largest number of drugs
including most PIs and NNRTIs
13. 13
Drug Effects on CYP450
Activity of CYP450 enzymes can be
affected by many medications
Drugs that affect CYP450 are
categorized as either inducers or
inhibitors
Drugs that are metabolized by
CYP450 (substrates) may be affected
by the presence of an inducer or an
inhibitor
16. Example: How a CYP450 Inducer
affects Substrates
16
Substrates
CYP450
Rifampin LPV and other
PIs, NVP, EFV:
• decreased
concentrations
• increased
activity of
CYP450
• faster
breakdown and
clearance of
other drugs
Inducer
17. Example: How a CYP450 Inhibitor
affects Substrates
17
Substrates
CYP450
Ritonavir
The 2nd
PIs:
•increased &
prolonged
concentrations
• decreased
activity of CYP450
• slower
breakdown and
clearance of other
drugs
Inhibitor
18. 18
Drug Effects on CYP450
Advantages:
Use of Ritonavir
(inhibitor) with
another PI leads to:
• higher, prolonged
blood levels
• decreases required
amount of 2nd PI
Disadvantages:
The use of
Rifampin with
many ARVs leads
to leads to
unacceptably low
blood levels of
these ARVs
20. 20
Rifampin and HIV Medications
By inducing the CYP450 enzyme,
Rifampin decreases blood levels of:
• PI
• NNRTI (NVP, EFV)
• Methadone
• Antifungal drugs
21. 21
Rifampin and ARV Blood Levels
SQV IDV NFV LPV NVP EFV
Rifampin
84%
89%
82%
75%
37%
25%
Finch et al. Arch Intern Med 2002;162:985-92
Do not use PIs with Rifampin
22. 22
Rifampin and NNRTIs (1)
Rifampin and NVP
NVP levels
decreased by 20-
58%
Clinical significance
of this is debated
Risk of
hepatotoxicity with
NVP and TB therapy
is also a concern
Rifampin and EFV
EFV levels
decreased by 26%
Not felt to have a
significant effect on
clinical outcomes
MOH guidelines
recommend EFV at
standard dosing
(600 mg/day) when
used with RIF
23. 23
Rifampin and NNRTIs (2)
In patients on TB therapy, EFV is the
preferred NNRTI
Patients on NVP at the time of TB
diagnosis should be changed to EFV
if possible
If EFV is not available, not tolerated
or contraindicated, NVP can be used
at standard doses
24. 24
Rifampin and LPV/r
RIF decreases LPV levels by > 75%
**Combination should be avoided if
possible
Patients who require RIF-based TB
therapy and PI-based ART can be
treated with “superboosted” LPV/r
• LPV 400 mg + RTV 400 mg twice daily
• Available by referral to provincial-level
OPC
25. 25
Case Study: Hung
Hung, a 26 year old HIV-positive man
presents to HIV OPC
• Has been on ART for about 3 months with
AZT, 3TC, NVP
• Baseline CD4 count was 67; Hb and ALT
normal
• Developed pulmonary TB and was recently
started on TB therapy (RHEZ)
Should his ART regimen be altered?
If so, how and why?
27. 27
Methadone + ARVs
ARV Effect Comment
EFV
↓ methadone
levels
(by 52%)
Can precipitate withdrawal
symptoms
May require increase in
methadone doseNVP
↓ methadone
levels
(by 41%)
LPV/r
↓ methadone
levels
(by 26 to 53%)
• Opioid withdrawal unlikely but
may occur
• Usually no adjustment in
methadone required
AZT
↑ AZT levels
(by 29-43%)
Monitor for AZT side effects
(e.g. anemia)
↓ ddI levels Use with caution
Source: US Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
Adolescents, January 10, 2011.
28. 28
Hormonal Contraceptives + ARVs
ARV
Effect on hormonal
contraceptive
Comment
EFV ↑ ethinyl estradiol
Use alternative or
additional methods
NVP ↓ ethinyl estradiol 20%
LPV/r ↓ ethinyl estradiol 42%
29. 29
Interactions among NRTIs
NRTI Pair
Results of
Interaction
Recommen-
dation
DDI + D4T •Increased toxicities
Avoid
combination
D4T + AZT
•Antagonistic effect
(require same enzymes for
intracellular
phosphorylation)
TDF + DDI
• Increased DDI toxicity
• Loss of CD4 responses
after time
• Suboptimal antiviral
response in regimens
with EFV
30. 30
How Can You Recognize and
Avoid Drug Interactions?
Review patient’s full medication list at every
visit
Recognize:
• drugs most commonly associated with
interactions (PIs, itraconazole, rifampin, etc.)
• medications with overlapping toxicities
• dietary restrictions with certain medications
Select agents with fewer drug interactions if
clinically appropriate
Simplify drug regimens whenever possible
31. 31
Look it Up!
When prescribing a new drug to a patient,
always look it up to make sure there aren’t any
drug interactions
References:
MOH Guidelines for the Diagnosis and Treatment of HIV/AIDS
www.HIV-druginteractions.org
www.AIDSinfo.nih.gov
32. 32
Key Points
4 components of pharmacokinetics
• All can affect success of drug therapy
Drug interactions are common when
treating PLHIV
• Many related to effects of the P450 liver
enzymes
• Important to recognize and avoid drug
interactions
M2-07-Pharmacokinetics and Drug Interactions-EN
HAIVN Module 2, Revised April 2012
Note that this slide is animated. Do not click through the answers on the slide until AFTER asking participants the question in the title.
ASK participants “What is pharmacokinetics?”
ALLOW time for them to answer, then click to show the answer.
ASK participants “What factors might affect drug distribution?”
ALLOW time for them to answer, then move to the next slide.
GIVE more examples of drugs absorbed better in an acidic environment:
Itraconazole
Ketoconazole
Indinivir
Atazanavir
EXPLAIN that when prescribing drugs which are absorbed better in acidic environment, patients should be counseled to:
avoid antacids
consider taking the medication with acidic drinks such as carbonated soft-drinks
EXPLAIN that ddI is better absorbed in a low acid environment. This is why it is formulated with a built in antacid (buffered) or protective coating (enteric coated).
The buffered formulation can decrease the absorption of other drugs because of the built-in antacid.
So when prescribing itraconazole, ketoconazole or indinavir with buffered ddI, the drug should be taken at least 1 hour apart.
EXPLAIN that distribution is the movement of the drug from the blood throughout the body. The action of most drugs is in the cells, not the blood, so distribution is how the drug gets from the blood to the site of action. For most ARV, the site of action is in the cells infected by HIV, such as the CD4 cells and others.
EXPLAIN that in general, drugs that have high protein binding have longer half-lives. However, the clinical relevance of changes in protein levels and protein binding is uncertain.
Note that this slide is animated. Do not click through the answers on the slide until AFTER asking participants the question in the title.
ASK participants “What is drug metabolism?”
ALLOW time for them to answer, and then click to show the answer on the screen.
EXPLAIN that metabolites can be active (have desired effects) or be inactive (have no medicinal effects).
EXPLAIN that we will discuss drub metabolism in more detail later in the session
EXPLAIN that all drugs must eventually be eliminated from the body. The kidney and the liver are the primary organs for drug excretion.
For metabolism through the liver and intestine: drugs can be excreted in the bile, or secreted directly into the intestinal tract
GIVE an example of how alkalinization of the urine affects drug excretion: increasing the pH of the urine from 6 to 8 will increase aspirin excretion by 4-6 times.
GIVE brief summary of what happens when a drug enters the body in general.
EXPLAIN that the Cytochrome P450 enzymes are one of the primary pathways for metabolizing drugs and toxins in the body. Many drugs used in HIV infection, including ARV, TB, and anti-fungal drugs, are metabolized this way.
EXPLAIN that CYP450 enzymes metabolize many drugs but the enzyme activity itself can also be affected by drugs.
STRESS that the most important inducer to know if Rifampin. We will see examples shortly of how it leads to serious drug interactions. Generally rifampin leads to decreased concentrations of other drugs and thus decreased effectiveness of those drugs.
EXPLAIN that many drugs are both inducers or inhibitors and also substrates of CYP450 themselves.
EXPLAIN this diagram:
An inducer, for example rifampin, affects CYP450 enzymes, leading to:
increased activity of CYP450 enzymes
faster breakdown and clearance of other drugs
decreased concentrations of other drugs
EXPLAIN that the most important inducer to know if Rifampin. Generally rifampin leads to decreased concentrations of other drugs and thus decreased effectiveness of those drugs
EXPLAIN this diagram:
An inhibitor, for example ritonavir, affects CYP450 enzymes, leading to:
decreased activity of CYP450 enzymes
slower breakdown and clearance of other drugs
increased and prolonged concentrations of other drugs
EXPLAIN that the most important inhibitor to know is ritonavir. Generally ritonavir leads to increased concentrations of many medications and thus increased risk of toxicity.
STRESS that induction or inhibition of CYP450 can have both advantages and disadvantages.
INTRODUCE that now you will review some important drug-drug interactions. Many of these are mediated through induction or inhibition of the CYP450 system.
EXPLAIN that Rifampin has interactions with many other drugs because it is a very strong inducer of the CP450 enzymes.
STRESS that PIs should not be used with Rifampin because the blood levels will be too low and ineffective.
EXPLAIN that some studies have demonstrate reduced virological outcomes with the use of NVP-containing ART and RIF-containing TB therapy while others have not.
EXPLAIN that some experts recommend increasing the dose of EFV to 800 mg/day in patients who weigh more than 60 kg, but most suggest that no dosage adjustment is necessary
GIVE an example of contraindication of EFV: patient is in the 1st trimester of pregnancy
CONCLUDE that it is OK to use NVP in a patient taking Rifampin
EXPLAIN that the Vietnam MOH HIV/AIDS guidelines recommend using EFV in patients who are also taking Rifampin, but allow using NVP if EFV is not available or if the patient can not take EFV. If using NVP with RIF, monitor closely for clinical symptoms of hepatitis and check liver enzyme level every 2 weeks
EXPLAIN that LPV/r is Lopinavir/Ritonavir .
REMIND that combination of RIF and a PI should be avoided whenever possible. However, in some cases these drugs must be used together. For example, a patient on second-line ART (TDF/3TC/LPV-r) who develops active TB. In this situation, the patient can be referred to the provincial level for superboosted LPV/r therapy. Superboosting LPV involves providing additional ritonavir to counteract the decreased LPV levels caused by RIF. The dose is LPV 400 mg / RTV 400 mg BID.
GIVE an example of how to get the superboosted dose: Aluvia 2 tabs + Ritonavir 3 tabs twice a day
STRESS that patients should be monitored very closely for liver toxicity and may have significant GI side effects on this regimen.
HAVE a participant read the case study and question presented on this slide.
ALLOW time for participants to discuss this question.
EXPLAIN that Hung’s ART regimen should be changed.
NVP should be changed to EFV
This is due to the interaction between Rifampin and NVP where-by Rifampin lowers NVP blood levels
It is also due to the higher risk of liver toxicity when using NVP and TB therapy together
If the patient cannot tolerate EFV, it is then acceptable to switch back to NVP
EMPHASIZE that interactions between ARVs and itraconazole are very important in Vietnam because of the incidence of penicillium marneffei infection.
Patients on Itraconazole for treatment of PM should be monitored closely for non-response and/or recurrence when NNRTI-based ART is given concomitantly.
Consideration should be given to increasing the dose of Itraconazole (especially during the maintenance phase; 200 mg/day to 400 mg/day) in this scenario.
EXPLAIN that similar concerns exist with the use of Itraconazole and Rifampin-based TB therapy.
Rifampin significantly decreases Itraconazole levels (decreased AUC by 80-90%) as well.
The combination should be avoided if possible.
MENTION that Ketoconazole has similar interactions as Itraconazole (decreased levels with NVP/EFV and increased with Aluvia)
BACKGROUND:
ITRA: Itraconazole
REF:
- Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol (2007) 63:451–456
- US DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 27, 2012
EXPLAIN that Methadone levels are decreased with co-administration with EFV, NVP, and LPV/r. Methadone dosing may need to be increased to avoid withdrawal symptoms.
EXPLAIN that ART affects levels of oral hormonal contraception. Patients should be advised to use additional methods especially when on EFV (risk of teratogenicity).
Note that this slide is animated. Do not click through the answers on the slide until AFTER asking participants the question in the title.
ASK participants “How can you recognize and avoid drug interactions?”
ALLOW time for them to answer, and then click to show the answer.
REMIND participants to review medications prescribed at other clinics (i.e. TB), private pharmacies, home remedies, etc.
GIVE example of medications with overlapping toxicities:
INH-D4T
DDI-D4T
AZT-ribavirin
GIVE example of dietary restrictions with certain medications:
DDI-empty stomach
EFV-empty stomach
EMPHASIZE that there are many drugs used to treat HIV patients and the number of potential interactions is too many to remember them all. If you are not sure about drug interactions between ARV and other drugs, then you can look it up.
REFER participants to Handout M2S7.1: Important Drug Interactions so that they can see further detail on drug interactions.